


LY288513

Cat. No.:	HY-103357
CAS No.:	147523-65-7
Molecular Formula:	C ₂₂ H ₁₈ BrN ₃ O ₂
Molecular Weight:	436.3
Target:	Cholecystkinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LY288513 is a selective non-peptide CCK-B receptor antagonist with an IC ₅₀ value of 16 nM. LY288513 produces an anxiolytic-like action in mice ^{[1][2][3]} .								
IC₅₀ & Target	IC ₅₀ : 16 nM (CCK-B receptor) ^[1]								
In Vitro	<p>LY288513 (10 nM; 2 days) suppresses the effects of CCK-8 on CD4⁺ T cell subset-specific transcription factors^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>RT-PCR^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>CD4⁺ T cells</td> </tr> <tr> <td>Concentration:</td> <td>10 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>2 days</td> </tr> <tr> <td>Result:</td> <td>Suppressed the effects of CCK-8 on CD4⁺ T cell subset-specific transcription factors.</td> </tr> </table>	Cell Line:	CD4 ⁺ T cells	Concentration:	10 nM	Incubation Time:	2 days	Result:	Suppressed the effects of CCK-8 on CD4 ⁺ T cell subset-specific transcription factors.
Cell Line:	CD4 ⁺ T cells								
Concentration:	10 nM								
Incubation Time:	2 days								
Result:	Suppressed the effects of CCK-8 on CD4 ⁺ T cell subset-specific transcription factors.								
In Vivo	<p>LY288513 (3, 10 mg/kg, i.p.; 10, 30 mg/kg, p.o.) produces an anxiolytic-like action in mice^[3]. LY288513 (1000 mg/kg, p.o.) potentiates the effects of a CNS depressant, slightly lowered body temperature, and had modest sedative effects only at the highest dose examined^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male CD-1 mice^[3]</td> </tr> <tr> <td>Dosage:</td> <td>3, 10 mg/kg; 10, 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; p.o.</td> </tr> <tr> <td>Result:</td> <td>Displayed anxiolytic-like effects in the elevated plusmaze.</td> </tr> </table>	Animal Model:	Male CD-1 mice ^[3]	Dosage:	3, 10 mg/kg; 10, 30 mg/kg	Administration:	i.p.; p.o.	Result:	Displayed anxiolytic-like effects in the elevated plusmaze.
Animal Model:	Male CD-1 mice ^[3]								
Dosage:	3, 10 mg/kg; 10, 30 mg/kg								
Administration:	i.p.; p.o.								
Result:	Displayed anxiolytic-like effects in the elevated plusmaze.								

REFERENCES

-
- [1]. Rasmussen K. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. *Ann NY Acad Sci.* 1994 Mar 23;713:300-11.
- [2]. Zhang JG, et al. Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4(+) T cells in vitro. *Int Immunopharmacol.* 2014;20(2):307-315.
- [3]. Helton DR, et al. Central nervous system characterization of the new cholecystokininB antagonist LY288513. *Pharmacol Biochem Behav.* 1996 Mar;53(3):493-502.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA